Top 50 Europe-based Pharmaceutical Company Selects eResearchTechnology to Provide Enterprise Electronic Data Capture Platform

Top 50 Europe-based Pharmaceutical Company Selects
eResearchTechnology to Provide Enterprise Electronic Data Capture Platform
Agreement Includes Enterprise License and Maintenance Services, With Potential
to Leverage Trial-based Site Support Services 


PHILADELPHIA, March 29  /PRNewswire-FirstCall/ -- eResearchTechnology, Inc.
(eRT), (NASDAQ:ERES), a leading e-research technology and services provider,
announced today that it has entered into an agreement with a top 50 Europe-
based pharmaceutical organization to provide an enterprise electronic data
capture (EDC) license and maintenance services.

The Enterprise EDC license agreement follows several years of partnering
between eRT and the sponsor to deploy EDC studies using the platform under a
subscription agreement.  Throughout the process, eRT provided comprehensive
knowledge and technology transfer services to support institutionalization of
EDC Best Practices in areas such as study design and site support services.

"eRT has enjoyed its collaboration with this thought leading organization for a
number of years, and we are delighted that key executives have elected to go
forward with an enterprise agreement, signaling broad adoption of EDC for this
sponsor across a number of clinical development programs," said Scott Grisanti,
senior vice president of business development and chief marketing officer at
eRT.  "Enterprise EDC adoption is critical to value maximization, and eRT's
comprehensive program of support throughout study implementation and conduct,
were key to this success story."

Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/) is a
provider of technology and services to the pharmaceutical, biotechnology and
medical device industries on a global basis.  The company is a market leader in
providing centralized core-diagnostic electrocardiographic (ECG) technology and
services to evaluate cardiac safety in clinical development. The company is
also a leader in providing technology and services to streamline the clinical
trials process by enabling its customers to automate the collection, analysis,
and distribution of clinical data in all phases of clinical development.

Statements included in this release may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
Such statements involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the company's ability to
obtain new contracts and accurately estimate net revenues due to variability in
size, scope and duration of projects, and internal issues in the sponsoring
client.  As a result, actual results may differ materially from any financial
outlooks stated herein.  Further information on potential factors that could
affect the company's financial results can be found in the company's Report on
Forms 10-K filed with the Securities and Exchange Commission. 

DATASOURCE: eResearchTechnology, Inc.



CONTACT:  Joan Sterlacci, eResearchTechnology, Inc., [phone]; or

Matt Hayden, Hayden Communications, [phone], for eResearchTechnology



Web site:  http://www.ert.com/ 

Copyright